Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Neurogene Inc (NGNE)

Neurogene Inc (NGNE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 267,667
  • Shares Outstanding, K 15,490
  • Annual Sales, $ 930 K
  • Annual Income, $ -75,140 K
  • EBIT $ -97 M
  • EBITDA $ -96 M
  • 60-Month Beta 1.60
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.96

Options Overview Details

View History
  • Implied Volatility 151.35% (-14.58%)
  • Historical Volatility 66.12%
  • IV Percentile 84%
  • IV Rank 39.74%
  • IV High 233.99% on 04/07/25
  • IV Low 96.85% on 11/26/25
  • Expected Move (DTE 3) 2.92 (17.23%)
  • Put/Call Vol Ratio 999.99
  • Today's Volume 1
  • Volume Avg (30-Day) 41
  • Put/Call OI Ratio 0.35
  • Today's Open Interest 917
  • Open Int (30-Day) 664
  • Expected Range 14.00 to 19.84

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.20
  • Number of Estimates 5
  • High Estimate -1.01
  • Low Estimate -1.59
  • Prior Year -0.99
  • Growth Rate Est. (year over year) -21.21%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.50 +1.21%
on 01/13/26
22.99 -27.36%
on 12/31/25
-4.22 (-20.17%)
since 12/12/25
3-Month
16.50 +1.21%
on 01/13/26
37.27 -55.19%
on 10/16/25
-14.92 (-47.19%)
since 10/13/25
52-Week
6.88 +142.73%
on 04/08/25
37.27 -55.19%
on 10/16/25
-2.11 (-11.22%)
since 01/13/25

Most Recent Stories

More News
Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome

Dosed multiple participants in Emboldenâ„¢ registrational trial in fourth quarter of 2025 Completion of dosing in Embolden expected in second quarter of 2026 ...

NGNE : 16.68 (-3.47%)
Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management...

NGNE : 16.68 (-3.47%)
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation...

NGNE : 16.68 (-3.47%)
Neurogene: Q3 Earnings Snapshot

Neurogene: Q3 Earnings Snapshot

NGNE : 16.68 (-3.47%)
Neurogene Reports Third Quarter 2025 Financial Results and Highlights Recent Updates

Reported positive interim data from NGN-401 Phase 1/2 gene therapy trial for Rett syndrome demonstrating multidomain, durable gains, with 35 total developmental milestones/skills acquired...

NGNE : 16.68 (-3.47%)
Neurogene Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome

Multidomain, durable gains with continued skill acquisition over time All 8 participants showed functional gains across spectrum of disease severity ...

NGNE : 16.68 (-3.47%)
Neurogene Announces First Participant Dosed in Emboldenâ„¢ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome

Single trial to support future BLA submission for NGN-401 in patients ages ≥ 3 years Rapid trial execution underway with 12 of 13 clinical sites initiated ...

NGNE : 16.68 (-3.47%)
Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation...

NGNE : 16.68 (-3.47%)
Craig-Hallum Keeps Their Buy Rating on Neurogene (NGNE)

In a report released today, Ryan Sigdahl from Craig-Hallum maintained a Buy rating on Neurogene. The company’s shares closed yesterday at $25.83.Elevate Your Investing Strategy: Take advantage of TipRanks...

NGNE : 16.68 (-3.47%)
Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Emboldenâ„¢ Registrational Trial in Q4 2025

Completed discussions with FDA on registrational protocol; 13 sites to allow for rapid enrollment New preclinical data at ESGCT Congress highlight NGN-401 best-in-class...

NGNE : 16.68 (-3.47%)

Business Summary

Neurogene Inc. is a clinical-stage company which bring life-changing genetic medicines to patients and families affected by rare neurological diseases. Neurogene Inc., formerly known as Neoleukin Therapeutics Inc., is based in NEW YORK.

See More

Key Turning Points

3rd Resistance Point 19.22
2nd Resistance Point 18.62
1st Resistance Point 17.95
Last Price 16.68
1st Support Level 16.68
2nd Support Level 16.08
3rd Support Level 15.41

See More

52-Week High 37.27
Fibonacci 61.8% 25.66
Fibonacci 50% 22.07
Fibonacci 38.2% 18.49
Last Price 16.68
52-Week Low 6.88

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar